Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) stock is making a run in the market this morning, but with no press releases or SEC filings, the big question is, “Why?” The gains are ultimately the result of an upgrade. Then again, we’re talking about gains of more than 60%. What is it about this analyst upgrade and … Read more
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) stock is making a run for the top in the market this morning, and for good reason. The company released positive Phase 3 data surrounding a diabetees treatment. Here’s what’s going on: Stop wasting your time! Start finding winning trades in minutes with Trade Ideas! LXRX Stock Rockets On Positive … Read more
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) is having an incredibly strong start to the trading session this morning, and for good reason. The company announced that it has received a drug approval from the European Commission. As you could imagine, the news excited investors who are pushing the stock on a run for the top. Today, … Read more
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) Lexicon Pharmaceuticals is having a great start to today’s trading session. At the opening bell, the stock was trading slightly in the green. However, as soon as trading started, we began to see incredibly strong upward movement. Below, we’ll talk about what we’re seeing from LXRX, why, and what we’ll … Read more
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) Lexicon Pharmaceuticals is having an incredible day in the market today, and for good reason. The company announced that a Phase 3 clinical trial met its primary endpoint. Today, we’ll talk about the results of the trial, how the stock reacted to the news, and what we can expect to … Read more
Lexicon Pharmaceuticals Declines After Yesterday’s Gains Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) Lexicon Pharmaceuticals had an incredible day in the market yesterday after releasing top-line data from its phase 3 study of telotristat etiprate. The study looked into the efficacy and tolerability with regard to the medication as a treatment for cancer patients with carcinoid syndrome. … Read more
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) Lexicon Pharmaceuticals is having a rough day in the market today. However, I don’t think that the declines are likely to last. The reality is that the company released incredibly positive data with regard to a phase 3 test of an experimental drug yesterday; which will likely prove to be … Read more
Lexicon Pharmaceuticals Climbs On Positive Phase 3 Data Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) Lexicon Pharmaceuticals is today’s biggest gainer in biotech; and for good reason. Early this morning, the company released data from it’s Phase 3 clinical trial, known as TELESTAR. The trial looked into the effectiveness of telotristat etiprate in treating cancer patients that … Read more
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) Lexicon Pharmaceuticals stock is having an incredible day in the market today after announcing the results from its Phase 3 clinical trial for its experimental drug known as telotristat etiprate. Today, we’ll take a look at the results of the study, how investors reacted, and what we can expect to … Read more